Front Row Advisors’s Gilead Sciences GILD Stock Holding History
Bought
Maintained
Sold
| Quarter | Market Value | Status | Shares |
Change in Stake | Trade Value | Portfolio Weight | Portfolio Position | |
|---|---|---|---|---|---|---|---|---|
|
2026
Q2 | $203K | Hold |
1,497
| – | – | 0.06% | 119 |
|
|
2026
Q1 | $209K | Hold |
1,497
| – | – | 0.07% | 108 |
|
|
2025
Q4 | $184K | Hold |
1,497
| – | – | 0.06% | 118 |
|
|
2025
Q3 | $166K | Sell |
1,497
-28
| -2% | -$3.18K | 0.06% | 124 |
|
|
2025
Q2 | $169K | Sell |
1,525
-58
| -4% | -$6.17K | 0.06% | 122 |
|
|
2025
Q1 | $177K | Buy |
1,583
+2
| +0.1% | +$206 | 0.07% | 133 |
|
|
2024
Q4 | $146K | Hold |
1,581
| – | – | 0.05% | 144 |
|
|
2024
Q3 | $133K | Hold |
1,581
| – | – | 0.05% | 155 |
|
|
2024
Q2 | $108K | Hold |
1,581
| – | – | 0.04% | 190 |
|
|
2024
Q1 | $116K | Buy |
1,581
+795
| +101% | +$61.1K | 0.04% | 164 |
|
|
2023
Q4 | $63.7K | Hold |
786
| – | – | 0.03% | 172 |
|
|
2023
Q3 | $58.9K | Hold |
786
| – | – | 0.03% | 222 |
|
|
2023
Q2 | $61K | Hold |
786
| – | – | 0.03% | 226 |
|
|
2023
Q1 | $65K | Buy |
786
+141
| +22% | +$11.7K | 0.03% | 220 |
|
|
2022
Q4 | $55K | Sell |
645
-141
| -18% | -$11.2K | 0.03% | 232 |
|
|
2022
Q3 | $49K | Buy |
786
+1
| +0.1% | +$63 | 0.03% | 246 |
|
|
2022
Q2 | $49K | Buy |
785
+2
| +0.3% | +$124 | 0.02% | 250 |
|
|
2022
Q1 | $47K | Buy |
783
+2
| +0.3% | +$128 | 0.02% | 267 |
|
|
2021
Q4 | $57K | Sell |
781
-249
| -24% | -$17.1K | 0.02% | 254 |
|
|
2021
Q3 | $72K | Buy |
1,030
+1
| +0.1% | +$70 | 0.03% | 231 |
|
|
2021
Q2 | $74K | Buy |
1,029
+2
| +0.2% | +$134 | 0.03% | 228 |
|
|
2021
Q1 | $66K | Buy |
1,027
+1
| +0.1% | +$64 | 0.03% | 231 |
|
|
2020
Q4 | $60K | Buy |
1,026
+2
| +0.2% | +$121 | 0.03% | 234 |
|
|
2020
Q3 | $61K | Sell |
1,024
-243
| -19% | -$16.9K | 0.03% | 225 |
|
|
2020
Q2 | $97K | Buy |
1,267
+1
| +0.1% | +$77 | 0.06% | 162 |
|
|
2020
Q1 | $106K | Buy |
1,266
+595
| +89% | +$41.1K | 0.07% | 148 |
|
|
2019
Q4 | $44K | Buy |
671
+1
| +0.1% | +$65 | 0.03% | 216 |
|
|
2019
Q3 | $42K | Sell |
670
-21
| -3% | -$1.37K | 0.03% | 216 |
|
|
2019
Q2 | $47K | Buy |
691
+512
| +286% | +$33.7K | 0.03% | 210 |
|
|
2019
Q1 | $12K | Buy |
179
+106
| +145% | +$7.04K | 0.01% | 407 |
|
|
2018
Q4 | $5K | Hold |
73
| – | – | ﹤0.01% | 533 |
|
|
2018
Q3 | $5 | Sell |
73
-88
| -55% | -$6.65K | ﹤0.01% | 554 |
|
|
2018
Q2 | $13 | Buy |
161
+23
| +17% | +$1.62K | 0.01% | 405 |
|
|
2018
Q1 | $10K | Buy |
138
+50
| +57% | +$3.98K | 0.01% | 435 |
|
|
2017
Q4 | $6K | Buy |
+88
| New | +$6.68K | ﹤0.01% | 507 |
|
Other funds holding GILD
Front Row Advisors's GILD Position: Q2 2026 in Review
Front Row Advisors held its Gilead Sciences (GILD) position steady in Q2 2026 at 1,497 shares worth $203K. The position accounts for 0.06% of the portfolio, ranked #119.
Front Row Advisors first reported a position in GILD in Q4 2017 and has held it in 35 quarters since. The position peaked at $209K in Q1 2026. 2,268 funds tracked by Wall St. Rank hold GILD as of Q2 2026.
- Front Row Advisors held 1,497 shares of Gilead Sciences worth $203K as of Q2 2026.
- Front Row Advisors left its Gilead Sciences share count unchanged in Q2 2026.
- Gilead Sciences made up 0.06% of Front Row Advisors's portfolio in Q2 2026, its #119 holding.
- Front Row Advisors first reported a position in Gilead Sciences in Q4 2017 and has held it in 35 quarters since.
- Front Row Advisors's Gilead Sciences position peaked at $209K in Q1 2026.
- 2,268 funds tracked by Wall St. Rank held Gilead Sciences as of Q2 2026.
Based on Front Row Advisors's 13F filing for Q2 2026, filed 13 Aug 2026.